The Biotech Growth Trust Plc Result of AGM

 
TIDMBIOG 
 
THE BIOTECH GROWTH TRUST PLC 
 
(the "Company") 
 
Results of the Annual General Meeting 
 
The Board is pleased to announce that at the Annual General Meeting (AGM) of the 
Company held on Thursday, 27 July 2023 all resolutions as detailed below were 
duly passed by shareholders on a poll. 
 
Resolutions     Votes For     %     Votes    %      Total     VotesWithheld* 
                                   Against        Votes Cast 
1. To accept    11,114,133  99.99   1,298   0.01  11,115,431      4,561 
the audited 
financial 
statements and 
the Report of 
the Directors 
for the year 
ended 31 March 
2023. 
2. To approve   11,060,592  99.58  46,591   0.42  11,107,183      12,809 
the Directors' 
Remuneration 
Report for the 
year ended 31 
March 2023. 
3. To approve   11,056,570  99.54  50,613   0.46  11,107,183      12,809 
the Directors' 
Remuneration 
Policy as set 
out on page 64 
of the Annual 
Report for the 
year ended 
31 March 2023. 
4. To re-elect  10,959,335  98.60  156,096  1.40  11,115,431      4,561 
Steve Bates as 
a Director of 
the Company. 
5. To re-elect  11,108,767  99.94   6,664   0.06  11,115,431      4,561 
Geoff Hsu as a 
Director of 
the Company. 
6. To re-elect  10,950,996  98.52  164,435  1.48  11,115,431      4,561 
Julia Le Blan 
as a Director 
of the 
Company. 
7. To re-elect  10,536,007  98.24  188,924  1.76  10,724,931     395,061 
Dr Nicki 
Shepherd as a 
Director of 
the Company. 
8. To re-elect  9,871,903   92.04  853,447  7.96  10,725,350     394,642 
The Rt Hon 
Lord Willetts 
as a Director 
of the 
Company. 
9. To re-elect  10,945,135  98.47  170,296  1.53  11,115,431      4,561 
Roger Yates as 
a Director of 
the Company. 
10. To re       11,076,784  99.68  35,132   0.32  11,111,916      8,076 
-appoint BDO 
LLP as auditor 
and to 
authorise the 
Audit 
Committee to 
determine 
their 
remuneration. 
11. To approve  11,103,500  99.97   3,556   0.03  11,107,056      12,936 
and adopt the 
amended 
investment 
policy as the 
investment 
policy of the 
Company in 
substitution 
for, and to 
the exclusion 
of, all 
previous 
investment 
policies of 
the Company. 
12. To          11,079,561  99.68  35,870   0.32  11,115,431      4,561 
authorise the 
Directors to 
allot 
securities in 
the Company. 
13#. To         11,068,162  99.58  47,108   0.42  11,115,270      4,722 
disapply the 
rights of pre 
-emption in 
relation to 
the allotment 
of securities. 
14#. To         11,084,178  99.71  32,169   0.29  11,116,347      3,645 
authorise the 
Company to 
make market 
purchases of 
Ordinary 
shares in the 
Company. 
15#. That the   11,090,838  99.78  24,538   0.22  11,115,376      4,616 
Directors be 
permitted to 
hold General 
Meetings 
(excluding the 
AGM) on not 
less than 14 
clear days' 
notice. 
 
# - Special Resolution 
 
* Please note that a `vote withheld' is not a vote in law and is not counted in 
the calculation of the proportion of votes `For' and `Against' a resolution. 
 
Any proxy votes which are at the discretion of the Chairman have been included 
in the "For" total. 
 
At the date of the AGM, the total number of Ordinary shares of 25p each in issue 
and the total number of voting rights was 37,247,029. 
 
The proxy voting figures will shortly also be available on the Company's website 
at www.biotechgt.com 
 
In accordance with Listing Rule 9.6.2, the full text of the resolutions passed 
has been submitted to the National Storage Mechanism and will shortly be 
available for inspection at 
https://data.fca.org.uk/#/nsm/nationalstoragemechanism. Resolutions 11 to 15 
will additionally be filed at Companies House. 
 
27 July 2023 
 
For further information please contact: 
 
Katherine Manson  Frostrow Capital LLP - Company Secretary  020 3709 8734 
 
 
This information was brought to you by Cision http://news.cision.com 
 
 
END

(END) Dow Jones Newswires

July 27, 2023 11:36 ET (15:36 GMT)

Biotech Growth (LSE:BIOG)
過去株価チャート
から 6 2024 まで 7 2024